| Congresso Brasileiro de Microbiologia 2023 | Resumo: 1058-2 | ||||
Resumo:Rates of colonization and infection with carbapenem-resistant Gram-negative pathogens are on the rise, particularly in Latin America countries, and this is increasingly true in Brazil as well. Gram-negative microorganisms, such as Pseudomonas aeruginosa and Acinetobacter baumannii are the most relevant pathogens responsible for particularly difficult-to-treat nosocomial infections, especially pneumonia, bloodstream and urinary tract infections. As the carbapenems have been the gold standard to date for the systemic treatment of serious infections with Gram-negative bacteria, carbapenem resistance presents new and difficult challenges in therapeutic decision-making, particularly because of the high frequency of coresistance. In addition, reports of polymyxin resistance in clinical isolates have recently increased, including acquired and intrinsically resistant pathogens. To document the status of carbapenem and polymyxin B-resistant producing non-fermenters isolated from different samples of Laboratório Cedro Method. The identification of isolated microorganisms was performed using mass spectrometry with the Microflex-Bruker Daltonics/BioTyper™ (MALDI-TOF) equipment (Bruker Daltonics GmbH and Co. KG - Bremen, Germany). The equipment was calibrated initially with the Bruker Bacterial Test Standard (BTS) as recommended by the manufacturer. To determine the susceptibility profile of the isolated bacteria in relation to antimicrobials, the Phoenix-BD equipment (Becton and Dickinson, Franklin Lakes, NJ, USA) and automated system Vitek2-CC4 (bioMérieux, Inc., Durham, NC, USA) with the AST-YS07 cards were used. For the polymyxin susceptibility test, the broth microdilution technique was employed to determine the minimum inhibitory concentration. For carbapenem-resistant microorganisms, the resistant test from automated system was confirmed using the Muller-Hinton and E-Test® bioMerieux gradient strips to determine the minimum inhibitory concentration (MIC). The results were interpreted based on the readings obtained from the cutoff points and analyzed according to the parameters established by the Brazilian Committee on Antimicrobial Susceptibility Testing (BrCast)/European Committee on Antimicrobial Susceptibility Testing guidelines. Non-fermenting bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii. Between 05/01/2021 to 05/31/2023, 1,652 strains of Acinetobacter baumannii isolated from hospital samples collected in the emergency room and during hospitalization were analyzed, 819 (49.6%) of which were female. Isolated from the respiratory, urinary and blood tracts accounted for 649 (39.3%), 377 (22.9%) and 332 (20%) respectively. Resistance to imipenem, meropenem and polymyxin B was observed in 1036 (62.7%), 1011 (61.2%) and 42 (4.5%) strains, respectively. Regarding Pseudomonas aeruginosa, a total of 4,573 strains of were isolated from samples collected during their visit to the emergency department or during hospitalization, of which 1,907 (41.7%) were female. Isolated from the respiratory tract, blood and urine accounted for 1,655 (36.2%), 1,067 (23.3%) and 878 (19.2%) respectively. Resistance to imipenem, meropenem and polymyxin B was observed in 2006 (43.9%), 1804 (39.5%) and 127 (6.5%) strains, respectively. Conclusion. These results are a concern since currently the carbapenems and polymyxins have been considered the most effective therapeutic option against MDR isolates of A. baumannii and P. aeruginosa. Palavras-chave: Acinetobacter baumannii, Bacterial resistance, Carbapenems, Polymyxins, Pseudomonas aeruginosa Agência de fomento:Laboratório Cedro | |||||